November 1, 2009
By:Jill Wechsler
FDA reviewers strive to assess new postmarketing programs while also evaluating applications.
 |
October 1, 2009
By:Jill Wechsler
Stiffer enforcement of research standards aims to restore the public's confidence in agency actions.
|
September 1, 2009
By:Jill Wechsler
International health crises expand testing of new vaccines and drug treatments for third-world diseases.
|
August 1, 2009
By:Jill Wechsler
Pressure to reduce health care spending puts R&D, costs, and coverage on the negotiating table.
|
July 1, 2009
By:Jill Wechsler
FDA leaders stress innovation and disclosure in promoting the agency's public health mission.
|
June 1, 2009
By:Jill Wechsler
Agency officials and sponsors anticipate stiffer oversight of research operations and disclosure requirements.
|
May 1, 2009
By:Jill Wechsler
Government funding slated to boost studies comparing medications to other treatments.
|
April 1, 2009
By:Jill Wechsler
Biomedical research community finds privacy policies add cost and complexity to clinical studies.
|
March 1, 2009
By:Jill Wechsler
Reformers seek disclosure of investigator payments and conflicts of interest.
|
| 
